Active DKK-1 vaccination has been characterized in vitro [116] and in vivo [117], and the improvement through the addition of antigens [118] or peptide sequences [119] has been evaluated for multiple myeloma, thereby increasing the potential therapeutic value of DKK-1 for this tumor. This evidence concerns the gene DKK1 and plasma cell myeloma.